Question 1

How are antigenic sites located on the glycoprotein?

Accepted Answer

By combining escape mutant selection under monoclonal antibody pressure with structural data on the folded protein. Sequencing the resistant variants points to residues, and mapping them onto the structure shows whether they cluster into a surface patch. Confirm by introducing the change into a clean background and retesting neutralisation.

Question 2

Why does passage history matter for sequence datasets?

Accepted Answer

Because growth in culture selects for receptor binding changes that sit close to antigenic sites and can be mistaken for immune escape. Record the passage history of every isolate, prefer sequences taken directly from clinical material where available, and state clearly how sequences with unknown history were handled in the analysis.

Question 3

Which methods detect selection at individual sites?

Accepted Answer

Codon-based models comparing non-synonymous and synonymous rates are standard, run in either a maximum likelihood or Bayesian framework. Test for recombination first, because unrecognised recombination generates false positives readily. Report the model, the tree, and the significance threshold, and treat any site list as a hypothesis for experimental follow-up rather than a result.

Question 4

How should a neutralisation panel be assembled?

Accepted Answer

Include antibodies of documented specificity spanning several antigenic sites, plus sera where population level recognition is the question. State the assay format, since plaque reduction, microneutralisation, and pseudovirus systems give values that are not interchangeable. Run reference viruses in every batch so that results months apart remain comparable.

Question 5

What role does glycan shielding play?

Accepted Answer

Added glycosylation sequons can mask epitopes without changing the underlying residues, so a variant may escape recognition through shielding rather than direct contact loss. Check predicted sequons against occupancy measured by mass spectrometry, since prediction alone overstates the number of sites actually carrying glycan.

Question 6

Which containment level does this research need?

Accepted Answer

It depends on the virus. Pseudovirus and recombinant glycoprotein systems allow much of the epitope work at containment level two, which is why many projects are designed around them. Handling the live pathogen raises the requirement, so confirm the level and secure approvals before planning any work with infectious stocks.

Microbiology

Microbiology

Research Frontiers in Viral Glycoprotein Antigenic Variation and Epitope Evolution